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ABSTRACT
Beta-2-microglobulin (B2M) is a marker of proximal tubular injury and glomerular filtration. Analyses using older/non-
standardized definitions have shown low efficacy of B2M to predict acute kidney injury (AKI). We assessed if elevated levels
of B2M would associate with either the diagnosis of AKI [under current Kidney Disease: Improving Global Outcomes (KDIGO)
criteria] or recovery from AKI. We performed a retrospective study, including children who had urine B2M (uB2M) and/or
serum B2M (sB2M) measured by immunoturbidimetry in our clinical laboratory between January 2011 and December 2015.
We defined AKI based on KDIGO criteria [increase of serum creatinine (sCr) 0.3 mg/dL over 48 h or >50% baseline over 7 days]
or urine output <0.5 mL/kg/h for 24 h. Recovery from AKI was defined as a return to baseline sCr within 6 months. We
calculated receiver operating characteristics (ROC) area under the curve (AUC). Of 529 patients, 245 developed AKI. Serum
and uB2M associated with AKI development (AUCs 0.84 and 0.73, respectively). Patients had a graded higher median sB2M
and uB2M with each higher AKI stage. sB2M differentiated Stage I from Stage III AKI (P<0.001) and Stage II from Stage III
AKI (P¼0.004). However, neither uB2M nor sB2M levels associated with recovery from AKI. Only older age {hazard ratio [HR]
0.97, [95% confidence interval (CI) 0.94–0.99]} and need for dialysis [HR 0.39 (95% CI 0.23–0.61)] predicted incomplete recovery
after AKI. Using KDIGO criteria, sB2M and uB2M associate with the severity of AKI. Given its relative ease and lower cost, we
suggest more widespread use of B2M for AKI detection.
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BACKGROUND
Acute kidney injury (AKI) often occurs in hospitalized patients
and is associated with increased morbidity and mortality [1]. The
incidence of AKI varied considerably in the past, partly due to the
use of many different definitions using variations of either serum
creatinine (sCr), urine output or need for dialysis [2, 3].
Standardized definitions and staging such as Risk, Injury, Failure,
Loss, End-stage renal disease (RIFLE) and the AKI Network (AKIN)
were recently merged into the current consensus Kidney Disease:
Improving Global Outcomes (KDIGO) definitions and staging [2,
4]. The Acute Kidney Injury–Epidemiologic Prospective
Investigation study was a multination cross-sectional study that
recently described the epidemiology of AKI in hospitalized adults
in 97 intensive care units (ICUs) from 33 different countries. Using
the KDIGO criteria, the overall incidence of AKI was 57% with
>30% developing KDIGO Stage III AKI [1]. Furthermore, AKI con-
ferred a clearly increased risk of chronic kidney disease (CKD) [es-
timated glomerular filtration rate (eGFR) at hospital discharge of
57 with AKI versus 95 without AKI; P< 0.001) and mortality (27%
with AKI versus 7% without AKI; P< 0.001) [1]. The incidence of
AKI in critically ill pediatric patients was recently reported as
23.6% by the Assessment of Worldwide Acute Kidney Injury,
Renal Angina and Epidemiology (AWARE) trial using the current
KDIGO standard definition [5]. They reported 11% mortality for
those with severe AKI (KDIGO Stage II or III) and found that severe
AKI increased the risk of death [odds ratio (OR) 1.77] [5]. Most im-
portantly, sCr alone failed to identify AKI in 18% of patients with
low urine output [3, 5, 6].
sCr, the historical surrogate for kidney function, used in the
RIFLE, AKIN and KDIGO classifications, does not increase until
significant kidney injury has already occurred. In pediatrics,
moreover, sCr levels change with age. Creatinine is falsely low
in children with chronic illness whose muscle mass is well be-
low normal, further complicating a creatinine-based AKI defini-
tion. Due to the imprecision of creatinine, multiple serum and
urine biomarkers have been investigated over the past decade
[7, 8].
Beta-2-microglobulin (B2M, molecular weight 12 000 Da) is a
component of the major histocompatibility antigen. By coupling
with the neonatal Fc receptor, it helps regulate serum levels of
immunoglobulin G, albumin and hepcidin [9]. It is hence impli-
cated in a multitude of disease processes, including glomerulo-
nephritis, AKI and iron overload diseases. B2M is filtered at the
glomerulus and 99.9% is reabsorbed by the proximal tubule.
B2M allows for functional assessment of both the glomerulus
and the renal tubules. In the 1980s, multiple studies analyzed
the ability of B2M to assess kidney function and found it in
most cases superior to sCr [10–12]. For the diagnosis of AKI, us-
ing older, nonstandardized definitions, Herget-Rosenthal et al.
[13] found that urine B2M (uB2M) performed poorly at predicting
the need for renal replacement therapy [area under the curve
(AUC) 0.51]. Under modified pediatric RIFLE (pRIFLE) criteria, Du
et al. [14] studied B2M and reported a low receiver operating
characteristics (ROC) curve AUC of 0.59 [14].
To date, B2M has not been studied using KDIGO criteria or
evaluated as a marker for kidney recovery or progression to
CKD after AKI. At our center we have routinely used B2M as a
marker for the diagnosis of AKI and monitoring kidney function
in children with CKD. We have used B2M both in outpatient
clinics to monitor patients recovering from AKI and to assess
for AKI in hospitalized patients. For outpatients, uB2M is used
more frequently to assess tubular function while using creati-
nine only for glomerular function. For inpatients, both uB2M
and serum B2M (sB2M) are used when possible, but this is lim-
ited in patients with anuric AKI. The aims of this study were to
compare B2M levels (serum and urine) between patients with
and without AKI (as defined by KDIGO) and determine the abil-
ity of elevated B2M levels to discriminate between AKI stages
and to assess the relationship between B2M elevation and re-
covery or progression to CKD after AKI.
MATERIALS ANDMETHODS
We performed a single-center retrospective cohort study to as-
sess if elevated levels of B2M, defined as serum levels >1.8 mg/L
or urine levels >0.2 mg/L (based on historical controls), would
diagnose AKI or predict recovery from or progression to CKD af-
ter AKI. We included all patients >1 year of age with a uB2M
and/or sB2M value determined in the St. Louis Children’s
Hospital clinical laboratory between January 2011 and
December 2015. We included patients in the outpatient clinic
and all inpatient units. B2M values in serum and urine were
assessed by immunoturbidimetry using a Cobas 6000 system
(Roche Diagnostics, Indianapolis, IN, USA). Our biomedical in-
formatics division then gathered pertinent clinical laboratory
data from our electronic medical record, which was then reviewed
and verified by one study team member (Kevin T. Barton). We
gathered data on baseline sCr (lowest value 3 months prior to B2M
lab draw when available), sCr at the time of B2M lab draw, maxi-
mum sCr during admission, sB2M, uB2M, urine protein, urine cre-
atinine, urine output and percent fluid overload over 24–48 h prior
to B2M lab draw. We also identified any past history of CKD, diag-
nosis on admission, lengths of hospital stay, ICU admission and
length of stay and recovery from AKI. This study was approved by
the institutional review board.
Using the KDIGO creatinine definition of AKI, we identified
patients who met the KDIGO sCr definition of AKI and its stages.
We used modified urine criteria of urine output <0.5 mL/kg/
h over 24 h, as charting in smaller time periods was incomplete.
Patients <1 year of age were excluded due to a lack of normative
values for B2M in this population at the time of the study.
Recovery was defined as a return to baseline sCr within
6 months of AKI. Time to recovery and degree of recovery were
recorded—complete or incomplete. If there was incomplete re-
covery, the stage of CKD was defined per standard criteria [15].
For comparisons between the AKI and no AKI groups, age
was analyzed using a Wilcoxon rank sum test and categorical
variables were analyzed using a chi-square test or Fisher’s exact
test, as appropriate. The sB2M and uB2M measures were ana-
lyzed using nonparametric approaches (Kruskal–Wallis and
Wilcoxon rank sum) to test for differences among AKI groups
and stages. The ability of sB2M and uB2M to predict AKI diagno-
sis was assessed using an ROC curve and the AUC statistic.
Univariable association of covariates with time to recovery from
AKI was analyzed using Cox regression analysis. Patients that
did not recover were censored at the most recent follow-up date
available in the database (date of lab draw up to 6 months after
hospital discharge or date of death). P-values <0.05 were consid-
ered significant.
RESULTS
Demographic characteristics
A total of 637 charts had available sB2M or uB2M results avail-
able in the study time period; 529 patients were >1 year of age
(Figure 1). Of these 529 244 total patients met the KDIGO
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definition of AKI and 285 patients had sB2M and/or uB2M test-
ing but did not meet the KDIGO definition of AKI.
There was a significant difference in age between the AKI
and no AKI groups (median 14.29 versus 9.89 years; P< 0.001;
Table 1). There was no difference between groups based on
race, gender or those with preexisting CKD. The most common
diagnosis was medication toxicity (n¼ 56) followed by primary
renal disease and dehydration (Table 1). There was a significant
difference between groups in percentages of heart transplant
recipients (P< 0.03 and P< 0.001), solid organ transplants overall
(P< 0.001), bone marrow transplant recipients (P¼ 0.004), viral
illness (P¼ 0.002) and sepsis (P< 0.001). There was no significant
association between AKI and time from transplant, suggesting a
more diverse range of causes than chronic medication/calci-
neurin toxicity. In patients who received a solid organ trans-
plant, the most common causes for AKI were medication
toxicity, dehydration and cardiac dysfunction. However, there
was not a significant difference between those with and with-
out AKI (Table 2).
Prediction of AKI
Serum and urine B2M were both strongly associated with AKI
development, with an AUC of 0.84 and 0.73, respectively
(Figure 2). The median values for sB2M and uB2M were signifi-
cantly higher in the AKI group versus the no AKI group (Table 3).
We analyzed patients who had both uB2M and sB2M values and
the results were nearly identical to when we included patients
who had only uB2M or sB2M. We only included analyses for
patients who had both uB2M and sB2M values. By the Kruskal–
Wallis test, patients also had a graded higher and significantly
different median sB2M and uB2M with each higher AKI stage
(Tables 3 and 4). Pairwise comparisons among stages revealed
that sB2M and uB2M differentiated between no AKI and Stage II
or III AKI (P< 0.001; Tables 4 and 5). sB2M also differentiated be-
tween no AKI and Stage I AKI (P< 0.001), Stages I and II AKI
(P< 0.001) and Stages II and III AKI (P¼ 0.004; Table 4). Although
there is literature supporting uB2M as a specific marker for
drug-induced AKI, we found no statistically significant differ-
ence in our population (Table 6).
Need for renal replacement therapy
Both uB2M and sB2M were associated with a need for renal re-
placement therapy. For this analysis we used all patients, not
just those with both uB2M and sB2M values, to account for an-
uric patients (Table 7).
Recovery from AKI
Of those 245 patients with AKI, our results showed 172 patients
had complete recovery, with 73 patients developing CKD or
death (66 CKD, 4 chronic dialysis, 12 died, not mutually exclu-
sive). Cox regression analysis indicated that older age and need
for dialysis were the only variables that were significantly asso-
ciated with a greater risk of not recovering after AKI {hazard ra-
tio [HR] 0.967 [confidence interval (CI) 0.941–0.993] and 0.388 (CI
0.233–0.610), respectively; Table 8}. Neither uB2M nor sB2M was
associated with the time-to-recovery outcome.
DISCUSSION
Our study highlights the ability of sB2M to identify patients
with AKI to a high degree of accuracy, using the newer and cur-
rent standardized and consensus KDIGO definition. Serum B2M
also showed a graded increase with increasing severity of AKI.
637 Charts 
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529 Pts > 1 
year of age
284 Pts 
with no AKI 
245 Pts  
with AKI
256 pts c 
UB2M 
values
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SB2M 
values
239 Pts 
with UB2M 
values
182 Pts c 
SB2M 
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recovery 73 pts 
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FIGURE 1: Consort style flow diagram.
Table 1. Demographic characteristics of study cohort
Variable
AKI
(n¼ 244)
No AKI
(n¼ 285) P-value
Age (years), mean (IQR) 14.29
(9.36–17.18)
9.89
(3.92–15.93)
<0.001
Male, n (%) 120 (49.2) 145 (50.9) 0.73
Race, n (%)
Caucasian 169 (69.6) 204 (71.6) 0.49
African American 56 (23.1) 67 (23.5)
Other 18 (7.4) 14 (4.9)
Diagnosis, n (%)
Medication toxicity 56 (23.0) 20 (7.0) <0.001
Primary renal disease 47 (19.3) 86 (30.2) 0.004
Dehydration 50 (20.5) 19 (6.7) <0.001
Solid organ transplant 41 (16.8) 22 (7.7) 0.001
Sepsis 37 (15.2) 9 (3.2) <0.001
Bone marrow transplant 21 (8.6) 8 (2.8) 0.004
Cardiac dysfunction 33 (13.5) 15 (5.3) 0.001
UTI 11 (4.5) 11 (3.9) 0.71
Viral illness 26 (10.7) 11 (3.9) 0.002
Prematurity 3 (1.2) 5 (1.8) 0.73
Other 111 (45.5) 162 (56.8) 0.009
Lung transplant 21 (8.6) 13 (4.6) 0.06
Liver transplant 6 (2.5) 5 (1.8) 0.57
Heart transplant 16 (6.6) 3 (1.1) <0.001
Kidney transplant 3 (1.2) 2 (0.7) 0.67
Table 2. Association between diagnosis and AKI in solid organ trans-
plant patients
Variable AKI (n¼ 41) No AKI (n¼ 22) P-value
Medication toxicity, n (%) 12 (29.3) 2 (9.1) 0.11
Dehydration, n (%) 12 (29.3) 1 (4.6) 0.024
Cardiac dysfunction, n (%) 9 (22.0) 2 (9.1) 0.30
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Urine B2M was also able to identify patients with AKI, but with
slightly less accuracy than sB2M. Neither uB2M nor sB2M were
significantly associated with recovery from AKI. Our study
showed that recovery was less likely in children who were older
or requiring renal replacement therapy during their AKI. These
results most likely reflect accumulation of nephrotoxicity from
chronic diseases such as congenital heart disease or refractory
malignancy in addition to their treatment regimes.
The ideal renal biomarker should have a regular production
rate and be eliminated only via glomerular filtration, without
tubular secretion or reabsorption. Creatinine has multiple limi-
tations as a biomarker, including tubular secretion and its de-
pendence on the patient’s muscle mass, age or gender. Most
importantly, it is a late and nonspecific marker of injury [16].
Our results show that B2M is strongly associated with AKI in
the pediatric population. Using KDIGO criteria versus pRIFLE cri-
teria, the AUC improved dramatically from the previously
reported 0.59 to our value of 0.84 for sB2M and 0.73 for uB2M.
Serum B2M was statistically significantly different between al-
most all stages of AKI, making it a potentially useful tool for es-
timating the functional severity of AKI. The uB2M values
peaked at Stage II AKI and decreased at Stage III, likely due to
decreased urine output in that group, limiting its utility at se-
vere stages of AKI. The higher AUC for sB2M compared with
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FIGURE 2: ROC curves for sB2M and uB2M versus AKI.
Table 3. sB2M and uB2M versus AKI
Variable AKI, median (IQR) No AKI, median (IQR) P-value
sB2M (mg/L) 4.4 (2.8–9.4) 1.9 (1.4–2.6) <0.001
uB2M (mg/L) 3.9 (0.4–17.3) 0.2 (0.2–2.9) <0.001
Table 4. Nonparametric analyses of sB2M and AKI stages
Group comparison
Group 1,
median (IQR)
Group 2,
median (IQR) P-value
No versus Stage I 1.9 (1.4–2.6) 3.1 (2.2–5) <0.001
No versus Stage II 1.9 (1.4–2.6) 3.8 (2.6–7.4) <0.001
No versus Stage III 1.9 (1.4–2.6) 5.7 (3.7–10.1) <0.001
Stage I versus Stage II 3.1 (2.2–5) 3.8 (2.6–7.4) 0.14
Stage I versus Stage III 3.1 (2.2–5) 5.7 (3.7–10.1) <0.001
Stage II versus Stage III 3.8 (2.6–7.4) 5.7 (3.7–10.1) 0.004
Table 5. Nonparametric analyses of uB2M and AKI stages
Group comparison
Group 1,
median (IQR)
Group 2,
median (IQR) P-value
No versus Stage I 0.2 (0.2–2.9) 1.5 (0.2–13.6) 0.028
No versus Stage II 0.2 (0.2–2.9) 8 (0.4–22.7) <0.001
No versus Stage III 0.2 (0.2–2.9) 3.7 (0.6–16.8) <0.001
Stage I versus Stage II 1.5 (0.2–13.6) 8 (0.4–22.7) 0.06
Stage I versus Stage III 1.5 (0.2–13.6) 3.7 (0.6–16.8) 0.10
Stage II versus Stage III 8 (0.4–22.7) 3.7 (0.6–16.8) 0.44
Table 6. uB2M versus drug-induced AKI
Variable
Drug-induced AKI, AKI (other causes),
P-valuemedian (IQR) median (IQR)
uB2M (mg/L) 3.5 (0.3–18.0) 3.1 (0.4–16.0) 0.92
Table 7. sB2M and uB2M versus dialysis (within AKI)
Variable
Dialysis, No dialysis,
P-valuemedian (IQR) median (IQR)
uB2M (mg/L) 9.5 (0.7–29.9) 2.6 (0.3–15.2) 0.043
sB2M (mg/L) 8.5 (5.5–14.2) 3.9 (2.7–8.3) <0.001
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uB2M is likely due to some prerenal AKI cases being classified
as Stage I KDIGO AKI, as would be expected.
To our knowledge, this is the first study to analyze B2M as a
marker for AKI under a standardized KDIGO definition. Previous
studies have analyzed multiple biomarkers using nonstandar-
dized or older definitions or specific populations. Du et al. [14], for
example, studied patients presenting to an emergency depart-
ment using pRIFLE criteria, with an AUC of 0.59 for uB2M. They
also examined neutrophil gelatinase-associated lipocalin (NGAL),
interleukin-18 and kidney injury molecule 1 (KIM-1), which all
had AUC values ranging from 0.44 to 0.66, comparable with B2M.
Compared with other newer biomarkers being developed, the
AUC of sB2M in mixed-etiology AKI populations compares favor-
ably with the AUCs of the newer biomarkers in similar mixed-eti-
ology populations, which range from 0.61–0.96 for NGAL to 0.69–
0.85 for KIM-1 and 0.70–0.75 for L-type fatty acid binding protein
(L-FABP) [8]. In the Translational Research Investigating
Biomarker Endpoints in AKI study, investigators found urine
NGAL, L-FABP and KIM-1 to be highly accurate markers of Stages
II and III AKI in pediatric cardiac surgery patients (AUC 0.75, 0.77
and 0.70, respectively), where the exact time of injury is known
and the type of injury is predominantly ischemic, thus bio-
markers tend to be more accurate [17]. Furthermore, sB2M can be
used for all hospitalized patients and not just those who are criti-
cally ill. However, we have not tested B2M versus the other bio-
markers head to head using common KDIGO criteria.
Although we found a significant association between uB2M
and sB2M with the need for renal replacement therapy, there
was significant overlap in B2M values between those who did
and did not need renal replacement therapy. The utility of B2M
as a predictor of renal replacement therapy is therefore limited,
but warrants further study.
Neither sB2M nor uB2M were significantly associated with
recovery from AKI, which may be due to the retrospective na-
ture of this study. Although there are consensus definitions for
recovery in adults, there is currently no corresponding defini-
tion of renal recovery after AKI in the pediatric population [18].
Most longitudinal follow-up studies are limited to dialysis re-
quirement or transplant, largely ignoring the early stage of CKD.
One report describes 34% of patients with residual CKD or
dialysis dependence after AKI [19]. More importantly, at the 3-
to 5-year follow-up, 60% of those patients who did completely
recover went on to develop signs of CKD, including proteinuria,
hypertension or decreased GFR [19]. This study highlights the
importance of longitudinal follow-up in patients with AKI, even
with apparent full recovery. Some of the newer biomarkers
such as NGAL, KIM-1 and L-FABP have moderately high AUCs of
0.67–0.82 for prediction of a composite outcome of AKI progres-
sion, dialysis or death in either cardiac bypass or mixed-etiology
critically ill populations [8]. To our knowledge, AUC data for the
isolated outcome of less than complete recovery from AKI in
mixed-etiology critically ill patients is not available for these
newer biomarkers.
There were multiple limitations to this study. Due to the
multifactorial nature of the causes of AKI, it is difficult to study
direct causality. As a retrospective chart analysis, there is al-
ways the possibility of missing or inaccurate data. Inherent in
our study also is a selection bias for patients who are likely to
have significant kidney injury and/or kidney disease and there-
fore had B2M tested. AKI in the neonatal population has new
criteria that were standardized after the completion of data col-
lection. We analyzed B2M versus AKI in this population and
subjectively it showed no difference between those with and
Table 8. Univariable time to event associations of covariates for like-
lihood of complete recovery from AKI
Variable HR (95% CI) P-value
Age (per year increment) 0.967 (0.941–0.993) 0.01
Urine protein (mg/dL) 0.999 (0.998–1.001) 0.39
Urine protein:creatinine ratio 0.991 (0.939–1.035) 0.72
Urine B2M (mg/L) 1.003 (0.998–1.008) 0.23
Serum B2M (mg/L) 0.984 (0.945–1.021) 0.41
Fractional excretion of B2M 1.11 (0.439–1.966) 0.79
Male 1.158 (0.857–1.567) 0.34
Race, Caucasiana 0.755 (0.533–1.088) 0.30
Race, other† 0.907 (0.468–1.64)
CKD 0.616 (0.33–1.052) 0.08
ICU 0.832 (0.613–1.125) 0.23
Solid organ transplant 0.761 (0.481–1.15) 0.20
Diagnosis, BMT 0.62 (0.306–1.115) 0.12
Dialysis 0.388 (0.233–0.61) <0.001
Lung transplant 0.698 (0.356–1.229) 0.23
Liver transplant 2.515 (0.886–5.579) 0.08
Heart transplant 0.833 (0.435–1.444) 0.54
Kidney transplant 0.94 (0.053–4.228) 0.95
aReference group for race was African American.
FIGURE 3: Box plots of sB2M and uB2M versus AKI.
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without AKI and a wider range of values in those without AKI
(Figure 3). This may be due to the maturation of tubular function
in this population. A future study could analyze this population
controlling more specifically for age and prematurity.
In addition, the timing of B2M draws was mostly at the time
of initial recognized elevated creatinine, but the exact timing
was inconsistent. We also only analyzed single measurements
of B2M per patient. In the future, serial measurements could
help clarify the role of B2M as a predictor of AKI and recovery
from AKI. Our lab does not adjust the pH of urine samples,
which may have affected our uB2M results. Furthermore, we
had to modify KDIGO urine output criteria, which may have
misidentified some early AKI as no AKI. However, using a longer
time period of decreased urine output would decrease the num-
ber of Stage I AKI patients detected, increasing the overall sever-
ity of the cohort. For recovery data, some patients were lost to
follow-up and were assumed to have not recovered, which may
not have been true.
B2M, while a better biomarker than creatinine, still has limi-
tations. It is increased in hematologic malignancies and multi-
ple autoimmune diseases such as Crohn’s disease and Sjo¨gren’s
syndrome and, importantly, lupus erythematosus. Despite
these limitations, B2M still showed high AUC values for the pre-
diction of AKI.
Multiple biomarkers have been identified and continue to be
studied in an attempt to identify AKI earlier and more accu-
rately to improve treatment and outcomes. We have shown
that B2M is a good predictor of AKI, but not necessarily specific
to the severity of AKI. Most importantly, with a unified defini-
tion through KDIGO criteria, we have shown B2M to be better at
predicting AKI development than has been previously reported.
With its relatively low cost ($2.45/test at our center) and poten-
tially wider clinical availability, we suggest B2M be imple-
mented more widely as a functional biomarker for AKI.
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